The Scientist

» biologics

Most Recent

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

image: Gene Therapy for Brain Disease

Gene Therapy for Brain Disease

By | May 16, 2012

Delivering a missing enzyme to the brains of paralyzed children with a rare, life-threatening neurological disease restores movement and builds muscle mass.

0 Comments

image: FDA Eases Sterility Requirements

FDA Eases Sterility Requirements

By | May 16, 2012

The US Food and Drug Administration has relaxed some of the rules governing how companies must test the sterility of materials used to make biologic drugs.

1 Comment

image: Size Matters to Industry

Size Matters to Industry

By | April 11, 2012

Large molecules are more likely to make it to market these days than small molecules, according to new reports.

0 Comments

image: FDA Discusses Biosimilars

FDA Discusses Biosimilars

By | August 8, 2011

The government says regulatory requirements for generic biological therapies will have to be tailored to the treatment in question.

3 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech